These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26808479)

  • 41. Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
    van der Vries E; Ip DK; Cowling BJ; Zhang JD; Tong X; Wojtowicz K; Schutten M; Boucher CA
    J Infect Dis; 2016 Jan; 213(2):183-90. PubMed ID: 26160744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
    Mohr PG; Geyer H; McKimm-Breschkin JL
    Antiviral Res; 2011 Jul; 91(1):20-2. PubMed ID: 21549758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir.
    Sato M; Honzumi K; Sato T; Hashimoto K; Watanabe M; Miyazaki K; Kawasaki Y; Hosoya M
    Pediatr Infect Dis J; 2014 Jul; 33(7):e168-72. PubMed ID: 24445826
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis of the Neuraminidase Amino Acid Sequences of Influenza A/H1N1pdm09, A/H3N2, and B Viruses Isolated from Influenza Patients in the 2013/14 Japanese Influenza Season].
    Ikematsu H; Chong Y; Shirane K; Toh H; Sasaki H; Koga Y; Matsumoto S; Hotta T; Uchiumi T; Kang D
    Fukuoka Igaku Zasshi; 2015 Aug; 106(8):231-9. PubMed ID: 26630841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
    Gubareva LV
    Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
    Bauer K; Richter M; Wutzler P; Schmidtke M
    Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
    Perez-Sautu U; Pozo F; Cuesta I; Monzon S; Calderon A; Gonzalez M; Molinero M; Lopez-Miragaya I; Rey S; Cañizares A; Rodriguez G; Gonzalez-Velasco C; Lackenby A; Casas I
    Euro Surveill; 2014 Jul; 19(27):14-20. PubMed ID: 25033052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Capacity building in national influenza laboratories--use of laboratory assessments to drive progress.
    Johnson LE; Muir-Paulik SA; Kennedy P; Lindstrom S; Balish A; Aden T; Moen AC
    BMC Infect Dis; 2015 Nov; 15():501. PubMed ID: 26546333
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measuring laboratory-based influenza surveillance capacity: development of the 'International Influenza Laboratory Capacity Review' Tool.
    Muir-Paulik SA; Johnson LE; Kennedy P; Aden T; Villanueva J; Reisdorf E; Humes R; Moen AC
    Public Health; 2016 Jan; 130():72-7. PubMed ID: 26531044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season.
    Meijer A; Lackenby A; Hay A; Zambon M
    Euro Surveill; 2007 Apr; 12(4):E3-4. PubMed ID: 17991386
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mapping of the US Domestic Influenza Virologic Surveillance Landscape.
    Jester B; Schwerzmann J; Mustaquim D; Aden T; Brammer L; Humes R; Shult P; Shahangian S; Gubareva L; Xu X; Miller J; Jernigan D
    Emerg Infect Dis; 2018 Jul; 24(7):1300-6. PubMed ID: 29715078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study.
    Bernard MC; Waldock J; Commandeur S; Strauß L; Trombetta CM; Marchi S; Zhou F; van de Witte S; van Amsterdam P; Ho S; Hoschler K; Lugovtsev V; Weir JP; Montomoli E; Cox RJ; Engelhardt OG; Friel D; Wagner R; Ollinger T; Germain S; Sediri-Schön H
    Front Immunol; 2022; 13():909297. PubMed ID: 35784305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening for Neuraminidase Inhibitory Activity in Traditional Chinese Medicines Used to Treat Influenza.
    Yang XY; Liu AL; Liu SJ; Xu XW; Huang LF
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27618892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results from the centers for disease control and prevention's predict the 2013-2014 Influenza Season Challenge.
    Biggerstaff M; Alper D; Dredze M; Fox S; Fung IC; Hickmann KS; Lewis B; Rosenfeld R; Shaman J; Tsou MH; Velardi P; Vespignani A; Finelli L;
    BMC Infect Dis; 2016 Jul; 16():357. PubMed ID: 27449080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved capacity for influenza surveillance in the WHO Eastern Mediterranean Region: Progress in a challenging setting.
    Malik MR; Abubakar A; Kholy AE; Buliva E; Khan WM; Lamichhane J; Moen A; McCarron M; Zureick K; Obtel M
    J Infect Public Health; 2020 Mar; 13(3):391-401. PubMed ID: 31522968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meeting the challenge of emerging pathogens: the role of the United States Air Force in global influenza surveillance.
    Williams RJ; Cox NJ; Regnery HL; Noah DL; Khan AS; Miller JM; Copley GB; Ice JS; Wright JA
    Mil Med; 1997 Feb; 162(2):82-6. PubMed ID: 9038023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pandemic Influenza Readiness Report on Laboratory and Epidemiology Capacity-United States and Territories, 2015.
    Lowe L; Dopson SA; Budd AP
    Health Secur; 2018; 16(4):239-243. PubMed ID: 30096246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison between the triglycerides standardization of routine methods used in Japan and the chromotropic acid reference measurement procedure used by the CDC Lipid Standardization Programme.
    Nakamura M; Iso H; Kitamura A; Imano H; Noda H; Kiyama M; Sato S; Yamagishi K; Nishimura K; Nakai M; Vesper HW; Teramoto T; Miyamoto Y
    Ann Clin Biochem; 2016 Nov; 53(6):632-639. PubMed ID: 26680645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. United States Centers for Disease Control and Prevention support for influenza surveillance, 2013-2021.
    McCarron M; Kondor R; Zureick K; Griffin C; Fuster C; Hammond A; Lievre M; Vandemaele K; Bresee J; Xu X; Dugan VG; Weatherspoon V; Williams T; Vance A; Fry AM; Samaan M; Fitzner J; Zhang W; Moen A; Wentworth DE; Azziz-Baumgartner E
    Bull World Health Organ; 2022 Jun; 100(6):366-374. PubMed ID: 35694628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Use of a Shared Services Model for Mycobacteriology Testing: Lessons Learned.
    Stafford C; Atkinson-Dunn R; Buss SN; Dalton T; Gibson D; Johnston S; King E; Grace Lin SY; Mitchell KK; Murtaugh WA; Sease H; Southern TR; Tans-Kersten JL; Travanty EA; Triplett LR; Wroblewski K; Starks AM
    Public Health Rep; 2018; 133(1):93-99. PubMed ID: 29258383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.